Literature DB >> 10999502

Therapeutic options in the treatment of clozapine-induced sialorrhea.

D P Rogers1, J K Shramko.   

Abstract

Clozapine is an effective atypical antipsychotic drug, but its use may be compromised by its side effects. Agranulocytosis may be fatal, but sialorrhea occurs more frequently and plays a major role in patients' noncompliance. A MEDLINE search from 1975-2000 revealed that treatment of clozapine-induced sialorrhea is predominantly based on case reports. Due to its elusive mechanism, physicians have attempted to treat this side effect with agents that counteract clozapine's adrenergic and muscarinic properties. We evaluated reported treatment options and other possible strategies from a pharmacologic standpoint. Antimuscarinic agents and alpha-receptor agonists are both viable options but must be administered and monitored cautiously in patients with psychiatric disorders. Although not yet available in the United States, pirenzepine, a selective muscarinic receptor antagonist, has the most promising mechanism. Other selective, peripherally acting agents must be investigated in controlled clinical trials to determine their efficacy as possible alternatives.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10999502     DOI: 10.1592/phco.20.13.1092.35036

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  10 in total

Review 1.  Clozapine-induced sialorrhea: pathophysiology and management strategies.

Authors:  Samir Kumar Praharaj; Manu Arora; Sachin Gandotra
Journal:  Psychopharmacology (Berl)       Date:  2006-03-03       Impact factor: 4.530

Review 2.  Pharmacological interventions for clozapine-induced hypersalivation.

Authors:  Rebecca Syed; Katie Au; Caroline Cahill; Lorna Duggan; Yanling He; Victor Udu; Jun Xia
Journal:  Cochrane Database Syst Rev       Date:  2008-07-16

3.  Clozapine-induced hypersalivation: an estimate of prevalence, severity and impact on quality of life.

Authors:  Senan Maher; Aoife Cunningham; Niamh O'Callaghan; Fintan Byrne; Colm Mc Donald; Shane McInerney; Brian Hallahan
Journal:  Ther Adv Psychopharmacol       Date:  2016-03-30

Review 4.  [Pharmacological strategies for clozapine-induced hypersalivation: treatment with botulinum toxin B in one patient and review of the literature].

Authors:  K G Kahl; P Trillenberg; A Kordon; R Lencer; C Klein; J Hagenah
Journal:  Nervenarzt       Date:  2005-02       Impact factor: 1.214

5.  Adverse Effects and Toxicity of the Atypical Antipsychotics: What is Important for the Pediatric Emergency Medicine Practitioner.

Authors:  J J Rasimas; Erica L Liebelt
Journal:  Clin Pediatr Emerg Med       Date:  2012-12-01

6.  Botulinum toxin B as an effective and safe treatment for neuroleptic-induced sialorrhea.

Authors:  Susanne Steinlechner; Christine Klein; Andreas Moser; Rebekka Lencer; Johann Hagenah
Journal:  Psychopharmacology (Berl)       Date:  2009-10-13       Impact factor: 4.530

7.  A successful treatment strategy for clozapine-induced parotid swelling: a clinical case and systematic review.

Authors:  Vyasa Immadisetty; Pradeep Agrawal
Journal:  Ther Adv Psychopharmacol       Date:  2012-12

8.  Botulinum toxin as an effective treatment of clozapine-induced hypersalivation.

Authors:  Kai G Kahl; Johann Hagenah; Silke Zapf; Peter Trillenberg; Christine Klein; Rebekka Lencer
Journal:  Psychopharmacology (Berl)       Date:  2004-01-28       Impact factor: 4.530

9.  The sublingual use of atropine in the treatment of clozapine-induced sialorrhea: A systematic review.

Authors:  Thomas Van der Poorten; Marc De Hert
Journal:  Clin Case Rep       Date:  2019-09-27

10.  Low-dose Amisulpride for Debilitating Clozapine-induced Sialorrhea: Case Series and Review of Literature.

Authors:  Ranganath R Kulkarni
Journal:  Indian J Psychol Med       Date:  2015 Oct-Dec
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.